Ultragenyx Pharmaceutical (RARE) Competitors $31.69 -0.33 (-1.03%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$32.36 +0.67 (+2.11%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. ROIV, MRNA, QGEN, BBIO, ELAN, VRNA, RVMD, CYTK, MRUS, and RNAShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Roivant Sciences (ROIV), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Cytokinetics (CYTK), Merus (MRUS), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors Roivant Sciences Moderna Qiagen BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Cytokinetics Merus Avidity Biosciences Ultragenyx Pharmaceutical (NASDAQ:RARE) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Which has more risk & volatility, RARE or ROIV? Ultragenyx Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Which has higher valuation & earnings, RARE or ROIV? Roivant Sciences has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Roivant Sciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M5.45-$569.18M-$5.53-5.73Roivant Sciences$23.23M482.04-$171.98M-$0.70-23.43 Does the media refer more to RARE or ROIV? In the previous week, Roivant Sciences had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 14 mentions for Roivant Sciences and 10 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.76 beat Roivant Sciences' score of 0.48 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend RARE or ROIV? Ultragenyx Pharmaceutical presently has a consensus target price of $81.50, indicating a potential upside of 157.18%. Roivant Sciences has a consensus target price of $19.94, indicating a potential upside of 21.57%. Given Ultragenyx Pharmaceutical's higher probable upside, equities research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is RARE or ROIV more profitable? Ultragenyx Pharmaceutical has a net margin of -87.34% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-87.34% -237.48% -37.66% Roivant Sciences -2,111.79%-15.90%-14.95% Do institutionals & insiders have more ownership in RARE or ROIV? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryRoivant Sciences beats Ultragenyx Pharmaceutical on 10 of the 17 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09B$3.36B$6.05B$10.52BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-5.7321.9085.0527.24Price / Sales5.45476.87595.29234.24Price / CashN/A46.9537.5761.53Price / Book11.4810.4312.676.74Net Income-$569.18M-$52.58M$3.32B$276.59M7 Day Performance2.69%-1.55%-1.34%-0.47%1 Month Performance9.28%12.96%8.11%7.47%1 Year Performance-44.52%15.43%78.90%34.58% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.2823 of 5 stars$31.69-1.0%$81.50+157.2%-43.6%$3.09B$560.23M-5.731,294Insider TradeROIVRoivant Sciences3.304 of 5 stars$16.26+0.6%$19.94+22.6%+38.5%$11.10B$23.23M-23.23860Insider TradeMRNAModerna4.2719 of 5 stars$27.54-3.3%$41.81+51.8%-54.5%$10.72B$3.24B-3.665,800QGENQiagen4.3061 of 5 stars$46.99+0.4%$49.40+5.1%+10.8%$10.45B$1.98B27.765,765Analyst DowngradeBBIOBridgeBio Pharma4.1338 of 5 stars$54.61+3.3%$63.94+17.1%+119.2%$10.44B$221.90M-13.35400ELANElanco Animal Health2.7755 of 5 stars$20.68+0.2%$18.33-11.3%+41.0%$10.27B$4.44B24.059,000VRNAVerona Pharma PLC American Depositary Share1.4518 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.114 of 5 stars$46.58-0.3%$74.64+60.2%-3.5%$8.71B$11.58M-10.35250CYTKCytokinetics3.6854 of 5 stars$60.64+6.4%$76.64+26.4%+12.0%$7.26B$18.47M-11.89250MRUSMerus0.8826 of 5 stars$94.270.0%$93.12-1.2%+81.8%$7.13B$36.13M-17.1437High Trading VolumeRNAAvidity Biosciences1.9737 of 5 stars$46.18-1.7%$68.32+47.9%+3.0%$6.74B$10.73M-12.97190Gap Down Related Companies and Tools Related Companies Roivant Sciences Alternatives Moderna Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Cytokinetics Alternatives Merus Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
